Latest Intelligence on Oncology in Switzerland

Published within

« | 1 | 2 | 3 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Roche: Xelox to challenge FOLFOX in colorectal cancer

A phase III trial of Roche's Xelox regimen in colorectal cancer has proven successful, with the study finding Xelox to be as effective as FOLFOX, the current standard first-line treatment for metastatic colorectal tumors. However, numerous challenges still face Roche if the regimen is to make a significant impact upon the colorectal tumor market.

Published By Datamonitor
02 Aug 2006
CommentWire
CommentWire

Roche: XELOX regimen may offer advantages over FOLFOX-4

Preliminary results show the combination of Xeloda plus Eloxatin, known as XELOX, to be equivalent to standard FOLFOX-4 chemotherapy treatment in terms of overall survival in first-line metastatic colorectal cancer patients. Given its dosing convenience advantage, XELOX has the potential to be a first-line treatment, provided it can be demonstrated as cost-effective.

Published By Datamonitor
23 Jan 2007
CommentWire
CommentWire

Roche: Xeloda gets warning on warfarin interaction

Like many drugs, and some foods, Xeloda interacts negatively with popular anticoagulant warfarin. This may reduce the use of Xeloda in cancer patients requiring anticoagulation. It also highlights the potential of AstraZeneca's new oral anticoagulant, ximelagatran, which is currently undergoing phase III trials and is not associated with the interactions that plague warfarin.

Published By Datamonitor
07 Nov 2001
CommentWire
CommentWire

Roche: poor results for NeoRecormon

Researchers have found that Roche's [ROCZ.S] anemia treatment NeoRecormon might worsen survival in head and neck cancer patients who undergo radiotherapy. Despite the poor findings, the study is unlikely to have any significant repercussions for NeoRecormon's rival erythropoietins, Amgen's [AMGN] Epogen and J&J's [JNJ] Procrit.

Published By Datamonitor
20 Oct 2003
CommentWire
CommentWire

Roche: Piramed acquisition strengthens its oncology and I&I portfolio

Roche has agreed to acquire Piramed for $160m plus a milestone payment of $15m, due upon the start of Phase II clinical trials for the company's oncology program. Piramed's oncology and immunology and inflammation programs will add to Roche's already strong portfolio in these therapy areas and the move is in line with Roche's strategy of pursuing these two fastest growing therapeutic segments.

Published By Datamonitor
15 Apr 2008
CommentWire
CommentWire

Roche: improved potential for MabThera

A phase III clinical trial of Roche's [ROCZg.VX] MabThera (rituximab) in patients below 60 years of age with aggressive non-Hodgkin's lymphoma was halted early because its primary efficacy endpoint was met two years earlier than expected. These trial results are likely to consolidate MabThera's position as the best-selling innovative agent for cancer.

Published By Datamonitor
08 Dec 2003
CommentWire
CommentWire

Roche: buying up for biotech boost

Roche has announced that it will acquire GlycArt for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies.

Published By Datamonitor
20 Jul 2005
CommentWire
CommentWire

Roche/Genentech: Herceptin poised for an expanded role

Scientists have found that HER-2 is a key contributor to the development of pre-invasive breast cancer. Roche/Genentech's Herceptin, currently used to treat advanced breast cancer, can target HER-2. However, the detection of elevated HER-2 is not routine among most physicians. Despite this, Herceptin is well positioned to build its usage in early-stage and pre-cancerous populations.

Published By Datamonitor
14 Apr 2003
CommentWire
CommentWire

Novartis: market experience will help Tasigna

Following the approval of Bristol-Myers Squibb's Sprycel in the US in June 2006 and EU in November 2006, Novartis has completed regulatory submissions for Gleevec follow-up Tasigna with both the FDA and EMEA. Despite Sprycel's first-to-market status, Novartis is well placed in the CML market via its experience with Gleevec to meet this challenge.

Published By Datamonitor
28 Nov 2006
CommentWire
CommentWire

Novartis: Glivec provides more impressive results

Patients with chronic myeloid leukemia (CML) receiving 800mg of Glivec are more likely to attain complete cytogenetic response compared to the standard dose of 400mg. If these preliminary results translate into improved survival for CML patients then this will undoubtedly secure further revenue for Novartis [NVS] as physicians switch to high dose Glivec.

Published By Datamonitor
07 Dec 2004

« | 1 | 2 | 3 | » »|

No help is available.